PTPN1 and neoplasm: A previous study has shown that targeting PTPN1 can improve T cell-mediated anti-tumor immunity and synergize with PD-1 checkpoint blockade and improve the efficacy of adoptively transferred chimeric antigen receptor (CAR) T cells (20).